Monoclonal antibody B43 Genistein-conjugate

Drug Profile

Monoclonal antibody B43 Genistein-conjugate

Alternative Names: B43-Gen; B43-Genistein; B43-Genistein conjugate; Monoclonal antibody B43-Gen

Latest Information Update: 18 Jan 2008

Price : $50

At a glance

  • Originator University of Minnesota
  • Developer Bristol-Myers Squibb; University of Minnesota
  • Class Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Acute lymphoblastic leukaemia; Cancer; Lymphoma

Most Recent Events

  • 01 Feb 2000 Clinical data have been added to the therapeutic trials section
  • 29 Mar 1999 A phase I study has been added to the pharmacokinetics, adverse events and therapeutic trials sections
  • 22 Mar 1999 Phase-I clinical trials for Acute lymphoblastic leukaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top